HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus

Abstract A novel coronavirus has been identified as an etiological agent of severe acute respiratory syndrome (SARS). To rapidly identify anti-SARS drugs available for clinical use, we screened a set of compounds that included antiviral drugs already in wide use. Here we report that the HIV-1 protease inhibitor, nelfinavir, strongly inhibited replication of the SARS coronavirus (SARS-CoV). Nelfinavir inhibited the cytopathic effect induced by SARS-CoV infection. Expression of viral antigens was much lower in infected cells treated with nelfinavir than in untreated infected cells. Quantitative RT-PCR analysis showed that nelfinavir could decrease the production of virions from Vero cells. Experiments with various timings of drug addition revealed that nelfinavir exerted its effect not at the entry step, but at the post-entry step of SARS-CoV infection. Our results suggest that nelfinavir should be examined clinically for the treatment of SARS and has potential as a good lead compound for designing anti-SARS drugs.

[1]  M. Chan-yeung,et al.  A cluster of cases of severe acute respiratory syndrome in Hong Kong. , 2003, The New England journal of medicine.

[2]  Obi L. Griffith,et al.  The Genome Sequence of the SARS-Associated Coronavirus , 2003, Science.

[3]  H. Doerr,et al.  Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus , 2003, The Lancet.

[4]  G. Zhaori.  Antiviral treatment of SARS: can we draw any conclusions? , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[5]  C. Terriff,et al.  Protease inhibitors: a therapeutic breakthrough for the treatment of patients with human immunodeficiency virus. , 1997, Clinical therapeutics.

[6]  J F Davies,et al.  Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. , 1997, Journal of medicinal chemistry.

[7]  Hz..  Glycyrrhizin , 2022 .

[8]  J. A. Comer,et al.  A novel coronavirus associated with severe acute respiratory syndrome. , 2003, The New England journal of medicine.

[9]  G. Pantaleo,et al.  Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count , 2000, AIDS.

[10]  W. Bellini,et al.  Effects of a SARS-associated coronavirus vaccine in monkeys , 2003, The Lancet.

[11]  C. Fraser,et al.  Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong , 2003, The Lancet.

[12]  Alexander E Gorbalenya,et al.  Mechanisms and enzymes involved in SARS coronavirus genome expression. , 2003, The Journal of general virology.

[13]  Malik Peiris,et al.  Aetiology: Koch's postulates fulfilled for SARS virus , 2003, Nature.

[14]  K. Yuen,et al.  Development of a standard treatment protocol for severe acute respiratory syndrome , 2003, The Lancet.

[15]  O. Kirk,et al.  A Randomized Trial Comparing Initial Haart Regimens of Nelfinavir/Nevirapine and Ritonavir/Saquinavir in Combination with Two Nucleoside Reverse Transcriptase Inhibitors , 2002, Antiviral therapy.

[16]  G. Pantaleo,et al.  Long-term kinetics of T cell production in HIV-infected subjects treated with highly active antiretroviral therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Christian Drosten,et al.  Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome , 2003, Science.

[18]  Elizabeth Rea,et al.  Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. , 2003, JAMA.

[19]  Christian Drosten,et al.  Identification of a novel coronavirus in patients with severe acute respiratory syndrome. , 2003, The New England journal of medicine.

[20]  Ton de Jong,et al.  Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques , 2004, Nature Medicine.

[21]  Peter Cameron,et al.  A major outbreak of severe acute respiratory syndrome in Hong Kong. , 2003, The New England journal of medicine.

[22]  P. Chan,et al.  Clinical presentations and outcome of severe acute respiratory syndrome in children , 2003, The Lancet.

[23]  Arthur S Slutsky,et al.  Identification of severe acute respiratory syndrome in Canada. , 2003, The New England journal of medicine.

[24]  L. Calza,et al.  Prospective comparison of first-line nelfinavir therapy versus nelfinavir introduction in rescue antiretroviral regimens. , 2003, AIDS patient care and STDs.

[25]  Hisashi Moriguchi,et al.  Treatment of SARS with human interferons , 2003, The Lancet.

[26]  J. Dennis,et al.  Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. , 2003, JAMA.